Comprehensive Stock Comparison
Compare Ainos, Inc. (AIMD) vs Adaptive Biotechnologies Corporation (ADPT) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth |  ADPT | 5.1% revenue growth vs AIMD's -83.0% |
| Quality / Margins | ADPT | -31.5% net margin vs AIMD's -132.3% |
| Stability / Safety |  AIMD | Beta 1.19 vs ADPT's 1.31 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | ADPT | +104.7% vs AIMD's -38.6% |
| Efficiency (ROA) | ADPT | -16.2% ROA vs AIMD's -65.9%, ROIC -41.6% vs -39.8% |
Who Each Stock Is For
Income & stability
AIMDDividend streak 0 yrs, beta 1.19
Growth exposure
ADPTRev growth 5.1%, EPS growth 30.8%, 3Y rev CAGR 5.1%
Long-term compounding (10Y)
ADPT-59.2% 10Y total return vs AIMD's -97.4%
Sleep-well-at-night portfolio
AIMDLower volatility, beta 1.19, Low D/E 77.3%, current ratio 1.10x
Defensive / Recession hedge
AIMDBeta 1.19, current ratio 1.10x
Business Model
What each company does and how it makes money
Ainos is a healthcare technology company developing point-of-care diagnostic tests and novel medical treatments. It generates revenue primarily from COVID-19 testing kits and related cloud-based management software — with additional income from its low-dose oral interferon alpha formulation and synthetic RNA platform. The company's competitive advantage lies in its integrated approach combining physical test kits with digital cloud-based management systems for healthcare providers.
Adaptive Biotechnologies is a biotechnology company that develops immune medicine platforms for diagnosing and treating diseases like cancer, autoimmune disorders, and infectious diseases. It generates revenue primarily through its clinical diagnostics segment — including its clonoSEQ test for minimal residual disease monitoring — and its translational and clinical genomics research services, with diagnostics contributing roughly 60% of revenue. The company's key advantage lies in its proprietary immune medicine platform that maps and translates the genetics of the adaptive immune system into clinical diagnostics and therapies.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
ADPT 4AIMD 0ADPT4/5 metricsADPT2/3 metricsADPT6/9 metricsADPT6/6 metricsADPT leads in 4 of 6 categories — strongest in Financial Metrics and Valuation Metrics. 1 category is tied.
Financial Metrics (TTM)
ADPT is the larger business by revenue, generating $253M annually — 2236.0x AIMD's $113,037. ADPT is the more profitable business, keeping -31.5% of every revenue dollar as net income compared to AIMD's -132.3%.
| Metric | AIMDAinos, Inc. | ADPTAdaptive Biotechn… |
|---|---|---|
| RevenueTrailing 12 months | $113,037 | $253M |
| EBITDAEarnings before interest/tax | -$10M | -$62M |
| Net IncomeAfter-tax profit | -$15M | -$80M |
| Free Cash FlowCash after capex | -$5M | -$63M |
| Gross MarginGross profit ÷ Revenue | +82.7% | +71.8% |
| Operating MarginEBIT ÷ Revenue | -126.7% | -30.9% |
| Net MarginNet income ÷ Revenue | -132.3% | -31.5% |
| FCF MarginFCF ÷ Revenue | -41.2% | -24.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +102.4% |
| EPS Growth (YoY)Latest quarter vs prior year | -93.9% | +126.6% |
Valuation Metrics
| Metric | AIMDAinos, Inc. | ADPTAdaptive Biotechn… |
|---|---|---|
| Market CapShares × price | $7M | $2.5B |
| Enterprise ValueMkt cap + debt − cash | $15M | $2.5B |
| Trailing P/EPrice ÷ TTM EPS | -0.97x | -15.22x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 349.20x | 14.02x |
| Price / BookPrice ÷ Book value/share | 0.92x | 11.94x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
ADPT delivers a -39.0% return on equity — every $100 of shareholder capital generates $-39 in annual profit, vs $-149 for AIMD. ADPT carries lower financial leverage with a 0.44x debt-to-equity ratio, signaling a more conservative balance sheet compared to AIMD's 0.77x. On the Piotroski fundamental quality scale (0–9), ADPT scores 4/9 vs AIMD's 2/9, reflecting mixed financial health.
| Metric | AIMDAinos, Inc. | ADPTAdaptive Biotechn… |
|---|---|---|
| ROE (TTM)Return on equity | -148.9% | -39.0% |
| ROA (TTM)Return on assets | -65.9% | -16.2% |
| ROICReturn on invested capital | -39.8% | -41.6% |
| ROCEReturn on capital employed | -50.0% | -32.0% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 4 |
| Debt / EquityFinancial leverage | 0.77x | 0.44x |
| Net DebtTotal debt minus cash | $8M | $41M |
| Cash & Equiv.Liquid assets | $4M | $48M |
| Total DebtShort + long-term debt | $12M | $89M |
| Interest CoverageEBIT ÷ Interest expense | -19.79x | -6.25x |
Total Returns (with DRIP)
A $10,000 investment in ADPT five years ago would be worth $3,893 today (with dividends reinvested), compared to $75 for AIMD. Over the past 12 months, ADPT leads with a +104.7% total return vs AIMD's -38.6%. The 3-year compound annual growth rate (CAGR) favors ADPT at 24.8% vs AIMD's -55.0% — a key indicator of consistent wealth creation.
| Metric | AIMDAinos, Inc. | ADPTAdaptive Biotechn… |
|---|---|---|
| YTD ReturnYear-to-date | -13.7% | +3.3% |
| 1-Year ReturnPast 12 months | -38.6% | +104.7% |
| 3-Year ReturnCumulative with dividends | -90.9% | +94.3% |
| 5-Year ReturnCumulative with dividends | -99.3% | -61.1% |
| 10-Year ReturnCumulative with dividends | -97.4% | -59.2% |
| CAGR (3Y)Annualised 3-year return | -55.0% | +24.8% |
Risk & Volatility
AIMD is the less volatile stock with a 1.19 beta — it tends to amplify market swings less than ADPT's 1.31 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ADPT currently trades 79.2% from its 52-week high vs AIMD's 33.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | AIMDAinos, Inc. | ADPTAdaptive Biotechn… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.19x | 1.31x |
| 52-Week HighHighest price in past year | $4.50 | $20.76 |
| 52-Week LowLowest price in past year | $1.26 | $6.26 |
| % of 52W HighCurrent price vs 52-week peak | +33.6% | +79.2% |
| RSI (14)Momentum oscillator 0–100 | 42.8 | 46.2 |
| Avg Volume (50D)Average daily shares traded | 829K | 1.8M |
Analyst Outlook
| Metric | AIMDAinos, Inc. | ADPTAdaptive Biotechn… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $21.25 |
| # AnalystsCovering analysts | — | 17 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 0 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Jan 21 | Mar 26 | Change |
|---|---|---|---|
| Ainos, Inc. (AIMD) | 100 | 2.75 | -97.2% |
| Adaptive Biotechnol… (ADPT) | 100 | 28.69 | -71.3% |
Adaptive Biotechnol… (ADPT) returned -61% over 5 years vs Ainos, Inc. (AIMD)'s -99%.
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Ainos, Inc. (AIMD) | $1975.00 | $20729.00 | +949.6% |
| Adaptive Biotechnol… (ADPT) | $38M | $179M | +365.5% |
Ainos, Inc.'s revenue grew from $0M (2015) to $0M (2024) — a 29.9% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2012 | 2024 | Change |
|---|---|---|---|
| Ainos, Inc. (AIMD) | -1228.0% | -717.0% | +41.6% |
| Adaptive Biotechnol… (ADPT) | -111.4% | -89.1% | +20.0% |
Ainos, Inc.'s net margin went from -1228% (2012) to -717% (2024).
Chart 4EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Ainos, Inc. (AIMD) | -0.39 | -1.56 | -300.0% |
| Adaptive Biotechnol… (ADPT) | -0.41 | -1.08 | -163.4% |
Ainos, Inc.'s EPS grew from $-0.39 (2015) to $-1.56 (2024).
Chart 5Free Cash Flow — 5 Years
Ainos, Inc. generated $-6M FCF in 2024 (-318% vs 2021). Adaptive Biotechnologies Corporation generated $-99M FCF in 2024 (+61% vs 2021).
AIMD vs ADPT: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is AIMD or ADPT a better buy right now?
Analysts rate Adaptive Biotechnologies Corporation (ADPT) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — AIMD or ADPT?
Over the past 5 years, Adaptive Biotechnologies Corporation (ADPT) delivered a total return of -61.1%, compared to -99.3% for Ainos, Inc. (AIMD). A $10,000 investment in ADPT five years ago would be worth approximately $4K today (assuming dividends reinvested). Over 10 years, the gap is even starker: ADPT returned -59.2% versus AIMD's -97.4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — AIMD or ADPT?
By beta (market sensitivity over 5 years), Ainos, Inc. (AIMD) is the lower-risk stock at 1.19β versus Adaptive Biotechnologies Corporation's 1.31β — meaning ADPT is approximately 10% more volatile than AIMD relative to the S&P 500. On balance sheet safety, Adaptive Biotechnologies Corporation (ADPT) carries a lower debt/equity ratio of 44% versus 77% for Ainos, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — AIMD or ADPT?
Adaptive Biotechnologies Corporation (ADPT) is the more profitable company, earning -89.1% net margin versus -717.0% for Ainos, Inc. — meaning it keeps -89.1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ADPT leads at -90.8% versus -667.7% for AIMD. At the gross margin level — before operating expenses — ADPT leads at 59.7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — AIMD or ADPT?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is AIMD or ADPT better for a retirement portfolio?
For long-horizon retirement investors, Ainos, Inc. (AIMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.19)). Both have compounded well over 10 years (AIMD: -97.4%, ADPT: -59.2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between AIMD and ADPT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.